202 related articles for article (PubMed ID: 35970756)
1. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
2. Landscape of
Kotmayer L; László T; Mikala G; Kiss R; Lévay L; Hegyi LL; Gróf S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulák A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szász R; Bödör C; Alpár D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982875
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Ahn IE; Davids MS
Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
6. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
7. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D; Beckmann L; Grimm C; Oliverio M; Meder L; Herling CD; Nieper P; Feldmann T; Merkel O; Lorsy E; da Palma Guerreiro A; von Jan J; Kisis I; Wasserburger E; Claasen J; Faitschuk-Meyer E; Altmüller J; Nürnberg P; Yang TP; Lienhard M; Herwig R; Kreuzer KA; Pallasch CP; Büttner R; Schäfer SC; Hartley J; Abken H; Peifer M; Kashkar H; Knittel G; Eichhorst B; Ullrich RT; Herling M; Reinhardt HC; Hallek M; Schweiger MR; Frenzel LP
Blood; 2022 Nov; 140(20):2113-2126. PubMed ID: 35704690
[TBL] [Abstract][Full Text] [Related]
8. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
[TBL] [Abstract][Full Text] [Related]
10. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
11. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
12. How I treat chronic lymphocytic leukemia after venetoclax.
Lew TE; Tam CS; Seymour JF
Blood; 2021 Aug; 138(5):361-369. PubMed ID: 33876212
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
14. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax resistance and acquired
Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
[No Abstract] [Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
18. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P; Lew TE; Dengler MA; Thompson ER; Lin VS; Chen X; Nguyen T; Panigrahi A; Handunnetti SM; Carney DA; Westerman DA; Tam CS; Adams JM; Wei AH; Huang DCS; Seymour JF; Roberts AW; Anderson MA
Blood; 2022 Feb; 139(8):1198-1207. PubMed ID: 34469514
[TBL] [Abstract][Full Text] [Related]
19. Genomics of Resistance to Targeted Therapies.
Thangavadivel S; Woyach JA
Hematol Oncol Clin North Am; 2021 Aug; 35(4):715-724. PubMed ID: 34174982
[TBL] [Abstract][Full Text] [Related]
20. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
